biomedicines

IMPACT FACTOR 3.9

Indexed in: PubMed

CITESCORE 5.2

an Open Access Journal by MDPI

Nutrient Sensing, Redox Homeostasis and Metabolic Diseases: Molecular Insight

Guest Editor:

Dr. Bal Krishna Chaube
Vascular Biology & Therapeutics Section, Department of Comparative Medicine, Yale University School of Medicine, New Haven, CT 06520, USA

Deadline for manuscript submissions:
closed (30 June 2023)

Message from the Guest Editor

The dysfunction of the metabolic system generally occurs due to the disturbance in energy balance, nutrient sensing, and altered redox homeostasis, leading to the development of various disorders, including diabetes, obesity, and cancer. An intervention involving diet manipulation or caloric restriction have shown some promising outcomes, including a delay in age-related disease. Pathways that mainly involve energy sensing and homeostasis are mTOR, sirtuins (SIRT1), AMPK, and insulin/insulin growth factor-1 (IGF-1). Alteration in these pathways may lead to altered nutrient sensing and redox homeostasis and thus the development of metabolic disorders. Understanding the mechanism behind how these pathways are altered during the progression or development of metabolic diseases could be beneficial for managing these diseases. For this Special Issue, we invite articles related to the areas of cellular or systemic metabolism, nutrient sensing, redox homeostasis, drugs mimicking dietary intervention, or caloric restrictions such as metformin and resveratrol in metabolic diseases including obesity, diabetes, cardiovascular, liver disorders, and cancers.

biomedicines

IMPACT FACTOR 3.9 | Indexed in: PubMed | CITESCORE 5.2

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
𝕏@Biomed_MDPI